S. Fogt, V. Kalugina, N. Vorokhobina, A. Kuznetsova, I. P. Serebryakova
{"title":"Сurrent肾上腺皮质癌治疗现状","authors":"S. Fogt, V. Kalugina, N. Vorokhobina, A. Kuznetsova, I. P. Serebryakova","doi":"10.21886/2219-8075-2022-13-2-154-161","DOIUrl":null,"url":null,"abstract":"Adrenocarcinoma is a rare adrenal disease with an unfavorable prognosis. Adrenocortical cancer therapy is characterized by insufficient effectiveness. This review covers the generally accepted adrenocortical carcinoma therapy methods -mitotane alone or in combination with chemotherapeutic agents. It also provides perspectives from the novel agents` studies in adrenocarcinoma patients. Information about the use of insulin-like growth factor inhibitors, multikinase inhibitors, anti-PD-1/PD-L1 is given.","PeriodicalId":18314,"journal":{"name":"Medical Herald of the South of Russia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Сurrent status of adrenocortical cancer therapy\",\"authors\":\"S. Fogt, V. Kalugina, N. Vorokhobina, A. Kuznetsova, I. P. Serebryakova\",\"doi\":\"10.21886/2219-8075-2022-13-2-154-161\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Adrenocarcinoma is a rare adrenal disease with an unfavorable prognosis. Adrenocortical cancer therapy is characterized by insufficient effectiveness. This review covers the generally accepted adrenocortical carcinoma therapy methods -mitotane alone or in combination with chemotherapeutic agents. It also provides perspectives from the novel agents` studies in adrenocarcinoma patients. Information about the use of insulin-like growth factor inhibitors, multikinase inhibitors, anti-PD-1/PD-L1 is given.\",\"PeriodicalId\":18314,\"journal\":{\"name\":\"Medical Herald of the South of Russia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Herald of the South of Russia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21886/2219-8075-2022-13-2-154-161\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Herald of the South of Russia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21886/2219-8075-2022-13-2-154-161","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Adrenocarcinoma is a rare adrenal disease with an unfavorable prognosis. Adrenocortical cancer therapy is characterized by insufficient effectiveness. This review covers the generally accepted adrenocortical carcinoma therapy methods -mitotane alone or in combination with chemotherapeutic agents. It also provides perspectives from the novel agents` studies in adrenocarcinoma patients. Information about the use of insulin-like growth factor inhibitors, multikinase inhibitors, anti-PD-1/PD-L1 is given.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
